27273307|t|Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome
27273307|a|Severe ovarian hyperstimulation syndrome (OHSS) is an iatrogenic condition that affects 1% of women that undergo treatment with assisted reproductive technology. The review aims to summarize recent evidence on pathophysiology, treatment, and prevention of OHSS. The pathophysiology is still not completely understood; however, vascular endothelial growth factor is likely to be an important mediator. Human chorionic gonadotropin was previously thought to be necessary for OHSS to occur; however, recent case reports have proven otherwise. The contribution of an attenuated anti-Mullerian hormone signalling pathway and CD11c + HLA-DR + dendritic cells and associated interleukins has been explored recently as contributors to pathogenesis. Treatment is largely supportive and is based mainly on consensus statements rather than evidence. Therefore, it is important to prevent this condition by identifying women at risk, allowing the clinician to implement preventive strategies, including the use of GnRH antagonist cycles with agonist triggers. More research is required to elucidate the pathophysiology behind the condition. Clinicians should employ strategies to prevent OHSS.
27273307	0	15	Pathophysiology	T169	C0031847
27273307	17	26	treatment	T061	C0087111
27273307	31	41	prevention	T061	C0199176
27273307	45	78	ovarian hyperstimulation syndrome	T047	C0085083
27273307	79	85	Severe	T080	C0205082
27273307	86	119	ovarian hyperstimulation syndrome	T047	C0085083
27273307	121	125	OHSS	T047	C0085083
27273307	133	143	iatrogenic	T080	C0439669
27273307	144	153	condition	T080	C0348080
27273307	159	166	affects	T077	C4054723
27273307	173	178	women	T098	C0043210
27273307	192	201	treatment	T061	C0087111
27273307	207	239	assisted reproductive technology	T061	C0872104
27273307	245	251	review	T170	C0282443
27273307	252	256	aims	T078	C1947946
27273307	260	269	summarize	T170	C1706244
27273307	270	276	recent	T079	C0332185
27273307	277	285	evidence	T078	C3887511
27273307	289	304	pathophysiology	T169	C0031847
27273307	306	315	treatment	T061	C0087111
27273307	321	331	prevention	T061	C0199176
27273307	335	339	OHSS	T047	C0085083
27273307	345	360	pathophysiology	T169	C0031847
27273307	374	384	completely	T080	C0205197
27273307	385	395	understood	T041	C0162340
27273307	406	440	vascular endothelial growth factor	T116,T123	C0078058
27273307	460	469	important	T080	C3898777
27273307	480	508	Human chorionic gonadotropin	T116,T121,T125	C1141639
27273307	524	531	thought	T041	C0039869
27273307	552	556	OHSS	T047	C0085083
27273307	560	565	occur	T052	C1709305
27273307	576	595	recent case reports	T170	C0007320
27273307	601	607	proven	T080	C0456369
27273307	623	635	contribution	T052	C1880177
27273307	642	652	attenuated	T052	C0599946
27273307	653	675	anti-Mullerian hormone	T116,T121,T125	C0066928
27273307	676	694	signalling pathway	T043	C0037083
27273307	699	704	CD11c	T116,T129,T192	C0023395
27273307	707	713	HLA-DR	T116,T129	C0019764
27273307	716	731	dendritic cells	T025	C0011306
27273307	736	746	associated	T080	C0332281
27273307	747	759	interleukins	T116,T129	C0021764
27273307	778	786	recently	T079	C0332185
27273307	790	802	contributors	T052	C1880177
27273307	806	818	pathogenesis	T046	C0699748
27273307	820	829	Treatment	T061	C0087111
27273307	841	851	supportive	T061	C0344211
27273307	859	864	based	T078	C1705938
27273307	875	884	consensus	T054	C0376298
27273307	885	895	statements	T078	C1710187
27273307	908	916	evidence	T078	C3887511
27273307	935	944	important	T080	C3898777
27273307	948	955	prevent	T169	C1292733
27273307	961	970	condition	T080	C0348080
27273307	974	985	identifying	T058	C1269815
27273307	986	991	women	T098	C0043210
27273307	992	999	at risk	T080	C1444641
27273307	1001	1009	allowing	T054	C0683607
27273307	1014	1023	clinician	T097	C0871685
27273307	1027	1036	implement	T052	C1708476
27273307	1037	1058	preventive strategies	T170	C0679716
27273307	1060	1069	including	T169	C0332257
27273307	1081	1096	GnRH antagonist	T121,T125	C1268855
27273307	1097	1103	cycles	T079	C0001289
27273307	1109	1116	agonist	T121	C2987634
27273307	1132	1140	research	T062	C0035168
27273307	1144	1152	required	T169	C1514873
27273307	1170	1185	pathophysiology	T169	C0031847
27273307	1197	1206	condition	T080	C0348080
27273307	1208	1218	Clinicians	T097	C0871685
27273307	1226	1232	employ	T169	C0457083
27273307	1233	1243	strategies	T041	C0679199
27273307	1247	1254	prevent	T061	C0679698
27273307	1255	1259	OHSS	T047	C0085083